BIG PHARMA EARNINGS WATCH: ABBVIE AND ASTRAZENECA

Big Pharma Giants Once Again Top Wall Street Expectations in Final Round of Fourth Quarter Earnings Reports While Continuing to Price-Gouge American Patients

A final round of Big Pharma 2022 fourth-quarter earnings reports from AbbVie and AstraZeneca showcases the pharmaceutical industry continues to ride high on blockbuster profits, fueled by price hikes and egregious anti-competitive tactics. Both brand name drug companies kept a Big Pharma Q4 winning streak going by reporting strong fourth-quarter earnings after engaging in price-gouging behavior or hiking prices over the last year.

AbbVie

AstraZeneca

The strong earnings come as both brand name drug manufacturers have received attention in recent years for engaging in – or planning – egregious price increases on prescription medications in their portfolios.

AbbVie

AstraZeneca

AstraZeneca has a long history of hiking prices on Americans struggling to afford their medications:

Read more on Q4 earnings from Merck, Sanofi, Bristol-Myers Squibb and Eli Lilly HERE.

Read more on Q4 earnings from Pfizer, Amgen, GlaxoSmithKline, Novartis and Johnson & Johnson HERE.

Learn more about solutions to lower prescription drug prices and hold Big Pharma accountable HERE.

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.